CAPTRUST Financial Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

CAPTRUST Financial Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-30,697	Closed	-$48K	–	2254
2022 Q3	$48K	Buy	30,697 +28,504	+1,300%	+$64.7K	﹤0.01%	1989
2022 Q2	$4K	Sell	2,193 -736	-25%	-$1.27K	﹤0.01%	4248
2022 Q1	$7K	Buy	2,929 +736	+34%	+$2.3K	﹤0.01%	4020
2021 Q4	$10K	Sell	2,193 -907	-29%	-$5.63K	﹤0.01%	3739
2021 Q3	$24K	Hold	3,100	–	–	﹤0.01%	3052
2021 Q2	$30K	Buy	3,100 +829	+37%	+$6.6K	﹤0.01%	2845
2021 Q1	$19K	Sell	2,271 -6,016	-73%	-$63.5K	﹤0.01%	3050
2020 Q4	$57K	Buy	8,287 +1,750	+27%	+$14.1K	﹤0.01%	1775
2020 Q3	$70K	Buy	6,537 +4,887	+296%	+$44.7K	﹤0.01%	1514
2020 Q2	$11K	Buy	+1,650	New	+$6.32K	﹤0.01%	2155
2019 Q4	–	Sell	-2,000	Closed	-$4K	–	1934
2019 Q3	$4K	Hold	2,000	–	–	﹤0.01%	1711
2019 Q2	$5K	Hold	2,000	–	–	﹤0.01%	1666
2019 Q1	$10K	Buy	+2,000	New	+$5.25K	﹤0.01%	1397

Other funds holding SRNE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BRF

B. Riley Financial Los Angeles, California $434M AUM 751.56% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

CAPTRUST Financial Advisors's SRNE Position: Q4 2022 in Review

CAPTRUST Financial Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2022, closing a stake of 30,697 shares — an estimated $48K sold.

CAPTRUST Financial Advisors first reported a position in SRNE in Q1 2019 and held it in 13 quarters. The position peaked at $70K in Q3 2020. 221 funds tracked by Wall St. Rank hold SRNE as of Q4 2022.

CAPTRUST Financial Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
CAPTRUST Financial Advisors sold 30,697 Sorrento Therapeutics, Inc. shares in Q4 2022, an estimated $48K.
CAPTRUST Financial Advisors first reported a position in Sorrento Therapeutics, Inc. in Q1 2019 and held it in 13 quarters.
CAPTRUST Financial Advisors's Sorrento Therapeutics, Inc. position peaked at $70K in Q3 2020.
221 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2022, filed 15 Feb 2023.